41 Tutorial on LC-MS/MS methods quantifying mAbs 17. US Food and Drug Administration. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines, 2001. https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM080538.pdf. Accessed on 22-10-2018. 18. An B, Zhang M, Qu J. Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. Drug Metab Dispos. 2014; 42: 1858-1866. 19. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu JF, Kamerud J, Ahene A, Myler H, Rogers C. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011; 13: 99-110. 20. Onami I, Ayabe M, Murao N, Ishigai M. A versatile method for protein-based antigen bioanalysis in nonclinical pharmacokinetics studies of a human monoclonal antibody drug by an immunoaffinity liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2014; 1334: 64-71. 21. Heudi O, Barteau S, Zimmer D, Schmidt J, Bill K, Lehmann N, Bauer C, Kretz O. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem. 2008; 80: 4200-4207. 22. Van Weemen BK, Schuurs AH. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 1971; 15: 232-236. 23. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry. 1971; 8: 871-874. 24. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005; 51: 2415-2418. 25. Voller A, Bartlett A, Bidwell DE. Enzyme immunoassays with special reference to ELISA techniques. J Clin Pathol. 1978; 31: 507-520. 26. Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, de Vries A. Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients. Ther Drug Monit. 2017; 39: 316-321. 27. Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum Antibodies. 2009; 18: 47-73. 28. Wild D. The immunoassay handbook: theory and applications of ligand binding, ELISA and related techniques. 2016. 29. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods. 2003; 278: 1-17. 30. Uotila M, Ruoslahti E, Engvall E. Two-site sandwich enzyme immunoassay with monoclonal antibodies to human alpha-fetoprotein. J Immunol Methods. 1981; 42: 11-15. 31. Savoie N, Garofolo F, van Amsterdam P, Bansal S, Beaver C, Bedford P, Booth BP, Evans C, Jemal M, Lefebvre M, Lopes de Silva AL, Lowes S, Marini JC, Masse R, Mawer L, Ormsby E, Rocci ML, Jr., Viswanathan C, Wakelin-Smith J, Welink J, White JT, Woolf E. 2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance. Bioanalysis. 2010; 2: 1945-1960. 2
RkJQdWJsaXNoZXIy MTk4NDMw